An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release
Cannabidiol (CBD), the major non-psychoactive phytocannabinoid found in cannabis, has anti-neuroinflammatory properties. Despite the increasing use of CBD, little is known about its effect in combination with other substances. Combination therapy has been gaining attention recently, aiming to produc...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/22/16254 |
| _version_ | 1797459019210686464 |
|---|---|
| author | Sigal Fleisher-Berkovich Veronica Battaglia Francesca Baratta Paola Brusa Yvonne Ventura Nitzan Sharon Arik Dahan Massimo Collino Shimon Ben-Shabat |
| author_facet | Sigal Fleisher-Berkovich Veronica Battaglia Francesca Baratta Paola Brusa Yvonne Ventura Nitzan Sharon Arik Dahan Massimo Collino Shimon Ben-Shabat |
| author_sort | Sigal Fleisher-Berkovich |
| collection | DOAJ |
| description | Cannabidiol (CBD), the major non-psychoactive phytocannabinoid found in cannabis, has anti-neuroinflammatory properties. Despite the increasing use of CBD, little is known about its effect in combination with other substances. Combination therapy has been gaining attention recently, aiming to produce more efficient effects. Angiotensin II activates the angiotensin 1 receptor and regulates neuroinflammation and cognition. Angiotensin receptor 1 blockers (ARBs) were shown to be neuroprotective and prevent cognitive decline. The present study aimed to elucidate the combined role of CBD and ARBs in the modulation of lipopolysaccharide (LPS)-induced glial inflammation. While LPS significantly enhanced nitric oxide synthesis vs. the control, telmisartan and CBD, when administered alone, attenuated this effect by 60% and 36%, respectively. Exposure of LPS-stimulated cells to both compounds resulted in the 95% inhibition of glial nitric oxide release (additive effect). A synergistic inhibitory effect on nitric oxide release was observed when cells were co-treated with losartan (5 μM) and CBD (5 μM) (by 80%) compared to exposure to each compound alone (by 22% and 26%, respectively). Telmisartan and CBD given alone increased TNFα levels by 60% and 40%, respectively. CBD and telmisartan, when given together, attenuated the LPS-induced increase in TNFα levels without statistical significance. LPS-induced IL-17 release was attenuated by CBD with or without telmisartan (by 75%) or telmisartan alone (by 60%). LPS-induced Interferon-γ release was attenuated by 80% when telmisartan was administered in the absence or presence of CBD. Anti-inflammatory effects were recorded when CBD was combined with the known anti-inflammatory agent dimethyl fumarate (DMF)/monomethyl fumarate (MMF). A synergistic inhibitory effect of CBD and MMF on glial release of nitric oxide (by 77%) was observed compared to cells exposed to MMF (by 35%) or CBD (by 12%) alone. Overall, this study highlights the potential of new combinations of CBD (5 μM) with losartan (5 μM) or MMF (1 μM) to synergistically attenuate glial NO synthesis. Additive effects on NO production were observed when telmisartan (5 μM) and CBD (5 μM) were administered together to glial cells. |
| first_indexed | 2024-03-09T16:46:28Z |
| format | Article |
| id | doaj.art-edeb0870d0c74125aed9c49ad6e320f8 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T16:46:28Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-edeb0870d0c74125aed9c49ad6e320f82023-11-24T14:46:47ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-11-0124221625410.3390/ijms242216254An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide ReleaseSigal Fleisher-Berkovich0Veronica Battaglia1Francesca Baratta2Paola Brusa3Yvonne Ventura4Nitzan Sharon5Arik Dahan6Massimo Collino7Shimon Ben-Shabat8Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 8410501, IsraelDepartment of Drug Science and Technology, University of Torino, 10124 Torino, ItalyDepartment of Drug Science and Technology, University of Torino, 10124 Torino, ItalyDepartment of Drug Science and Technology, University of Torino, 10124 Torino, ItalyDepartment of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 8410501, IsraelDepartment of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 8410501, IsraelDepartment of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 8410501, IsraelDepartment of Neuroscience “Rita Levi Montalcini”, University of Torino, 10124 Torino, ItalyDepartment of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 8410501, IsraelCannabidiol (CBD), the major non-psychoactive phytocannabinoid found in cannabis, has anti-neuroinflammatory properties. Despite the increasing use of CBD, little is known about its effect in combination with other substances. Combination therapy has been gaining attention recently, aiming to produce more efficient effects. Angiotensin II activates the angiotensin 1 receptor and regulates neuroinflammation and cognition. Angiotensin receptor 1 blockers (ARBs) were shown to be neuroprotective and prevent cognitive decline. The present study aimed to elucidate the combined role of CBD and ARBs in the modulation of lipopolysaccharide (LPS)-induced glial inflammation. While LPS significantly enhanced nitric oxide synthesis vs. the control, telmisartan and CBD, when administered alone, attenuated this effect by 60% and 36%, respectively. Exposure of LPS-stimulated cells to both compounds resulted in the 95% inhibition of glial nitric oxide release (additive effect). A synergistic inhibitory effect on nitric oxide release was observed when cells were co-treated with losartan (5 μM) and CBD (5 μM) (by 80%) compared to exposure to each compound alone (by 22% and 26%, respectively). Telmisartan and CBD given alone increased TNFα levels by 60% and 40%, respectively. CBD and telmisartan, when given together, attenuated the LPS-induced increase in TNFα levels without statistical significance. LPS-induced IL-17 release was attenuated by CBD with or without telmisartan (by 75%) or telmisartan alone (by 60%). LPS-induced Interferon-γ release was attenuated by 80% when telmisartan was administered in the absence or presence of CBD. Anti-inflammatory effects were recorded when CBD was combined with the known anti-inflammatory agent dimethyl fumarate (DMF)/monomethyl fumarate (MMF). A synergistic inhibitory effect of CBD and MMF on glial release of nitric oxide (by 77%) was observed compared to cells exposed to MMF (by 35%) or CBD (by 12%) alone. Overall, this study highlights the potential of new combinations of CBD (5 μM) with losartan (5 μM) or MMF (1 μM) to synergistically attenuate glial NO synthesis. Additive effects on NO production were observed when telmisartan (5 μM) and CBD (5 μM) were administered together to glial cells.https://www.mdpi.com/1422-0067/24/22/16254microglianitric oxidelipopolysaccharidecannabidioltelmisartan |
| spellingShingle | Sigal Fleisher-Berkovich Veronica Battaglia Francesca Baratta Paola Brusa Yvonne Ventura Nitzan Sharon Arik Dahan Massimo Collino Shimon Ben-Shabat An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release International Journal of Molecular Sciences microglia nitric oxide lipopolysaccharide cannabidiol telmisartan |
| title | An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release |
| title_full | An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release |
| title_fullStr | An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release |
| title_full_unstemmed | An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release |
| title_short | An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release |
| title_sort | emerging strategy for neuroinflammation treatment combined cannabidiol and angiotensin receptor blockers treatments effectively inhibit glial nitric oxide release |
| topic | microglia nitric oxide lipopolysaccharide cannabidiol telmisartan |
| url | https://www.mdpi.com/1422-0067/24/22/16254 |
| work_keys_str_mv | AT sigalfleisherberkovich anemergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT veronicabattaglia anemergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT francescabaratta anemergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT paolabrusa anemergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT yvonneventura anemergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT nitzansharon anemergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT arikdahan anemergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT massimocollino anemergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT shimonbenshabat anemergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT sigalfleisherberkovich emergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT veronicabattaglia emergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT francescabaratta emergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT paolabrusa emergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT yvonneventura emergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT nitzansharon emergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT arikdahan emergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT massimocollino emergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease AT shimonbenshabat emergingstrategyforneuroinflammationtreatmentcombinedcannabidiolandangiotensinreceptorblockerstreatmentseffectivelyinhibitglialnitricoxiderelease |